This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.
1 citations
,
September 2013 in “Revue d'Épidémiologie et de Santé Publique” Higher unemployment rates are linked to increased suicide rates, especially in men aged 25-49 in France.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.
November 2024 in “Circulation” This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.
March 2025 in “Scientific Reports” This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.